



Bullish Growth Stocks Weekend Note


6/20/2022

Nick Smith





Key names in group: VRTX AMGN HALO UTHR KDNY SIGA
RGC LEGN



Medical-Biomed/Biotech

Symbol	Company	Mkt Cap (mil)
AMGN	Amgen Inc	125,387
GILD	Gilead Scien...	73,414
VRTX	Vertex Pharm...	67,286
REGN	Regeneron P...	63,815
MRNA	Moderna Inc	50,925
SGEN	Seagen Inc	30,455
BNTX	Biontech Se ...	30,348
BIIB	Biogen Inc	29,545
RPRX	Royalty Phar...	23,892
HZNP	Horizon Ther...	18,972
GMAB	Genmab A/S ...	18,718
ARGX	Argenx SE Ads	17,479
ALNY	Alnylam Phar...	16,562
INCY	Incyte Corpor...	15,786
BMRN	Biomarin Pha...	14,074
BGEN	Beigene Ltd ...	13,633
BHVN	Biohaven Ph...	10,311
UTHR	United Thera...	9,937
NBIX	Neurocrine Bi...	8,915
LEGN	Legend Biote...	7,130
MRVI	Maravai Lifes...	6,798
EXAS	Exact Scienc...	6,513
HALO	Halozyme Th...	6,089
EXEL	Exelixis Inc	5,952
SRPT	Sarepta Ther...	5,859
CRSP	Crispr Thera...	5,422
ITCI	Intra-Cellular ...	5,182
AZTA	Azenta Inc	5,149
IONS	Ionis Pharma...	4,999
ASND	Ascendis Ph...	4,779
APLS	Apellis Phar...	4,701
ALKS	Alkermes Plc	4,580
EVO	Evotec Se Ads	4,028
RARE	Ultragenyx P...	3,726
TPTX	Turning Point...	3,698
CERE	Cerevel Ther...	3,547
GLPG	Galapagos N...	3,530
CYTK	Cytokinetics Inc	3,475
DNA	Ginkgo Biow...	3,274
VIR	Vir Biotechno...	3,245
ABCM	Abcam plc Ads	3,213
NTLA	Intellia Thera...	3,209
ACAD	Acadia Phar...	3,149
NVAX	Novavax Inc	3,144
KRTX	Karuna Ther...	3,136
ARND	Arrowhead P...	2,070

Show All Component Data

Short Interest 2.2 days +4%

Shares Outstanding 255.8 Million

\$263.09 +8.21
Volume 8,495,200 +3.22%
Last Updated: 4:00 PM ET 06/17/22


50-Day Avg Volume	1,684,400
-------------------	-----------

Off 52-Week High -10.1%

52-Week Hi-Lo \$292.75-\$176.36

Top RS in Grp	Symbol	RS	EPS Rtg	No. of Funds	
BeliteBio	BLTE	99	59	Jun-21	2694
SigaTech	SIGA	99	51	Sep-21	2666
Tricida	TCDA	99	37	Dec-21	2739
RegencellBio	RGC	99	34		
SierraOnco	SRRA	99	30	Mar-22	2900

Quarterly	EPS(\$)	%Chg	Sales(\$Mil)	% Chg
Jun-20	2.61	+107%	1524.5	+62%
Sep-20	2.64	+115%	1538.3	+62%
Dec-20	2.51	+48%	1627.8	+15%
Mar-21	2.98	+16%	1724.3	+14%
Jun-21	3.11	+19%	1793.4	+18%
Sep-21	3.56	+35%	1984.2	+29%
Dec-21	3.37	+34%	2072.6	+27%
Mar-22	3.52	+18%	2097.5	+22%



Institutional Ownership

Funds	59%
Banks	1%
Insurance Co.	0%

Management Ownership

Percentage Held	1%
Outstanding Shares	256 Mil

Fund Ownership Summary

Date	No of Funds
Jun-20	2550
Sep-20	2598
Dec-20	2605
Mar-21	2613
Jun-21	2694
Sep-21	2666
Dec-21	2739
Mar-22	2900

IBD Mutual Fund Index Ownership

MFS Growth A				0.76%
Jun-21	Sep-21	Dec-21	Mar-22	
1.11M	1.10M	1.11M	1.25M	

Fidelity Contrafund				0.58%
Jun-21	Sep-21	Dec-21	Mar-22	
1.54M	0.94M	1.39M	2.30M	

[Show Fund Ownership](#)

Halozyyme Therapeutics

Add to List: [IPO](#) [Add to Watchlist](#) [Add to Portfolio](#) [Add to Favorites](#) [Add to Alerts](#) [Add to News](#) [Add to Research](#) [Add to Social](#)

Halozyyme Therapeutics (HALO) NASDAQ Medical-Biomed/Biotech (85/197)

www.halozyyme.com

Options Yes

Short Interest 8.0 days -3%

Market Capitalization \$6089.1 Million

Shares in Float 133.8 Million

Shares Outstanding 137.9 Million

\$44.14 +0.35
+0.80%

Volume 6,479,300 +27%

Last Updated: 4:00 PM ET 06/17/22

HEADQUARTERS: San Diego, CA PHONE: 858-794-8889 EPS Due 8/9/2022e

DEVELOPS RECOMBINANT HUMAN ENZYMES AND NOVEL ONCOLOGY THERAPIES THAT TARGET THE TUMOR MICROENVIRONMENT.

05/24/22 Acquired Antares Pharma Inc, for \$5.60 per share in cash

50-Day Avg Volume 1,021,500

Off 52-Week High -9.1%

52-Week Hi-Lo \$48.58-\$31.36


Year (Dec)	EPS (\$)	Price(\$) High	Low	EPS Rating	44
2015	-0.25	25	9	Group RS Rating	57
2016	-0.81	17	6	SMR Rating	A
2017	0.45	21	9	Acc/Dis Rating	C+
2018	-0.56	21	13	Composite Rating	89
2019	-0.50▲	19	13	Timeliness Rating	B
2020	1.13▲	44	12	Sponsorship Rating	C
2021	2.00	56	31	EPS Growth Rate	N/A
2022	2.11 est	6%		Earnings Stability	N/A
2023	2.84 est	35%		P/E Ratio	21 (1.3 X SP)

Yield	NONE	Return on Equity	169%
ExDiv	N/A	Cash Flow	\$2.17

Book Value	x30.92	Debt	400%	Ownership	
Inventory T/O	7.73X	R&D	8.0%	Mgmt	2%
U/D Vol Ratio	1.4	Alpha	0.09	Banks	0%
New CEO	01/2014	Beta	0.99	Funds	60%

Top RS in Grp	Symbol	RS	EPS Rtg	No. of Funds
BeliteBio	BLTE	99	59	Jun-21 634
SigaTech	SIGA	99	51	Sep-21 646
Tricida	TCDA	99	37	Dec-21 656
RegencellBio	RGC	99	34	Mar-22 641
SierraOnco	SRRA	99	30	

Quarterly	EPS(\$)	%Chg	Sales(\$Mil)	% Chg
Jun-20	0.24	#+340%	55.2	+41%
Sep-20	0.31	#+282%	65.3	+41%
Dec-20	0.56	#+333%	121.7	+127%
Mar-21	0.37	+999%	89.0	+251%
Jun-21	0.66	+175%	136.5	+147%
Sep-21	0.55	+77%	115.8	+77%
Dec-21	0.42	-25%	102.0	-16%
Mar-22	0.47	+27%	117.3	+32%



HALO

Institutional Ownership

Funds	60%
Banks	0%
Insurance Co.	0%

Management Ownership

Percentage Held	2%
Outstanding Shares	138 Mil

Fund Ownership Summary

Date	No of Funds
Jun-20	457
Sep-20	483
Dec-20	588
Mar-21	622
Jun-21	634
Sep-21	646
Dec-21	656
Mar-22	641

IBD Mutual Fund Index Ownership

Invesco Discovery A			1.14%
Jun-21	Sep-21	Dec-21	Mar-22
0.86M	1.00M	1.12M	1.23M

Show Fund Ownership

United Therapeutics Corp (UTHR) NASDAQ [Medical-Biomed/Biotech \(85/197\)](#)
[www.unither.com](#)

Options Yes

Short Interest 3.3 days -19%

Market Capitalization

\$9937.7 Million

Shares in Float

39.4 Million

Shares Outstanding

45.3 Million

\$219.38 -1.27 -0.58%

Volume 2,724,100 +19%

Last Updated: 4:00 PM ET 06/17/22

HEADQUARTERS: Silver Spring, MD

PHONE: 301-608-9292

IPO 6/17/1999

EPS Due 8/4/2022e

50-Day Avg Volume 462,200

DEVELOPS THERAPIES TO TREAT CARDIOVASCULAR AND INFECTIOUS DISEASES AND CANCER.

Off 52-Week High -7.1%

04/01/21 Received FDA approval for Tyvaso, for the treatment of pulmonary hypertension with interstitial lung disease.

52-Week Hi-Lo \$236.06-\$158.38


Year (Dec)	EPS (\$)	Price(\$) High	Low
2015	12.29	190	117
2016	15.58	159	97
2017	16.53	169	112
2018	15.36	152	100
2019	13.06	128	74
2020	14.46	152	75
2021	15.26	218	145
2022	18.52	est	21%▲
2023	20.45	est	10%▲

Yield	NONE
ExDiv	N/A
Book Value	x2.51
Inventory T/O	18.70X
U/D Vol Ratio	1.7
New CEO	06/2016

Top RS in Grp	Symbol	RS	EPS Rtg	No. of Funds
BeliteBio	BLTE	99	59	Jun-21 844
SigaTech	SIGA	99	51	Sep-21 872
Tricida	TCDA	99	37	Dec-21 897
RegencellBio	RGC	99	34	Mar-22 881
SierraOnco	SRRA	99	30	

Quarterly	EPS(\$)	%Chg	Sales(\$Mil)	% Chg
Jun-20	3.68	+1%	362.0	-3%
Sep-20	3.88	+1%	380.1	-5%
Dec-20	3.31	+69%	384.9	+24%
Mar-21	3.49	-3%	379.1	+6%
Jun-21	4.09	+11%	446.5	+23%
Sep-21	4.16	+7%	444.7	+17%
Dec-21	3.51	+6%	415.2	+8%
Mar-22	5.03	+44%	461.9	+22%

UTHR broke out on heavy volume and drifted lower and is testing recent breakout pivot. On daily chart there is a little pivot forming around 222 that might allow cheat entry on upside



HEADQUARTERS: Somerset, NJ

PHONE: 732-317-5050

IPO 6/5/2020

EPS Due 8/23/2022e

50-Day Avg Volume

594,300

DEVELOPS NOVEL CELL THERAPIES FOR ONCOLOGY AND OTHER INDICATIONS.

Off 52-Week High

-20.3%

05/09/22 Named Lori Macomber CFO, effective immediately, replacing Ying Huang who will remain CEO


52-Week Hi-Lo

\$58.00-\$30.75

Year (Dec)	EPS (\$)	Price(\$) High Low	EPS Rating	
2015			19	
2016			57	
2017			E	
2018	-0.02		B+	
2019	-1.01		68	
2020	-1.69	43 24	C	
2021	-2.71	58 23	C	
2022	-1.10	est N/A		
2023	-0.87	est N/A		
Yield	NONE		EPS Growth Rate	N/A
ExDiv	N/A		Earnings Stability	N/A
Book Value	x15.13		P/E Ratio	N/A
Inventory T/O	50.60X		5-Year P/E Range	N/A
U/D Vol Ratio	1.5		Return on Equity	[N/A]
New CEO	09/2020		Cash Flow	\$-2.38
Top RS in Grp		Symbol	RS	EPS Rtg
BeliteBio		BLTE	99	59
SigaTech		SIGA	99	51
Tricida		TCDA	99	37
RegencellBio		RGC	99	34
SierraOnco		SRRA	99	30

Quarterly	EPS(\$)	%Chg	Sales(\$Mil)	% Chg
Jun-20	-0.42	N/A	11.6	+15%
Sep-20	-0.50	N/A	11.8	-34%
Dec-20	-0.44	N/A	40.8	+110%
Mar-21	-0.60	N/A	13.7	+18%
Jun-21	-0.66	N/A	20.2	+74%
Sep-21	-0.61	N/A	16.9	+44%
Dec-21	-0.82	N/A	39.0	-4%
Mar-22	-0.50	N/A	40.8	+198%

Debt	26%	Ownership	
R&D	99.9%	Mgmt	13%
Alpha	0.20	Banks	0%
Beta	1.08	Funds	98%



Institutional Ownership

Funds	98%
Banks	0%
Insurance Co.	0%

Management Ownership

Percentage Held	13%
Outstanding Shares	154 Mil

Fund Ownership Summary

Date	No of Funds
Jun-20	172
Sep-20	110
Dec-20	89
Mar-21	93
Jun-21	100
Sep-21	104
Dec-21	241
Mar-22	279

IBD Mutual Fund Index Ownership

Federated Hermes Kaufm...			0.54%
Jun-21	Sep-21	Dec-21	Mar-22
1.07M	0.95M	0.95M	1.05M

Show Fund Ownership

Regencell Bioscience Hld (RGC) NASDAQ [Medical-Biomed/Biotech \(85/197\)](#)
www.regencellbioscience.com

Options No
 Short Interest 0.7 days -4%

Market Capitalization \$551.4 Million
 Shares in Float 2.3 Million
 Shares Outstanding 13.0 Million

\$42.52 +0.02
 Volume 93,400 +0.05%
 Last Updated: 3:33 PM ET 06/17/22

HEADQUARTERS: HONG KONG PHONE: IPO 7/16/2021 EPS Due 1/1/0001e
 HONG KONG-BASED CO DEVELOPS TRADITIONAL CHINESE MEDICINE TO TREAT NEUROCOGNITIVE DISORDERS AND DEGENERATION.
 06/17/22 No news available

50-Day Avg Volume 20,100
 Off 52-Week High -27.9%
 52-Week Hi-Lo \$59.00-\$6.00

Year (Jun)	EPS (\$)	Price(\$) High Low	EPS Rating	
2014			Group RS Rating	34
2015			SMR Rating	57
2016			Acc/Dis Rating	N/A
2017			Composite Rating	A
2018			Timeliness Rating	74
2019	-0.03		Sponsorship Rating	B
2020	-0.06		EPS Growth Rate	N/A
2021			Earnings Stability	N/A
2022			P/E Ratio	N/A
			5-Year P/E Range	N/A
Yield		NONE	Return on Equity	[N/A]
ExDiv		N/A	Cash Flow	\$-0.06
Book Value		x-207.99	Debt	N/A
Inventory T/O		N/A	R&D	N/A
U/D Vol Ratio		2.5	Alpha	1.69
New CEO		N/A	Beta	1.54

Top RS in Grp	Symbol	RS	EPS Rtg	No. of Funds
BeliteBio	BLTE	99	59	Jun-21 N/A
SigaTech	SIGA	99	51	Sep-21 3
Tricida	TCDA	99	37	Dec-21 1
SierraOnco	SRRA	99	30	
Pharvaris	PHVS	99	8	Mar-22 4

Quarterly	EPS(\$)	%Chg	Sales(\$Mil)	% Chg
Mar-19	-0.01	N/A	N/A	N/A
Jun-19	-0.01	N/A	N/A	N/A
Sep-19	-0.01	N/A	N/A	N/A
Dec-19	-0.01	N/A	N/A	N/A
Mar-20	-0.02	N/A	N/A	N/A
Jun-20	-0.02	N/A	N/A	N/A
Sep-20	-0.01	N/A	N/A	N/A
Dec-20	-0.01	N/A	N/A	N/A



Year (Dec)	EPS (\$)	Price(\$) High Low	EPS Rating	
2015	-0.73	2 1	Group RS Rating	51
2016	-0.69▲		SMR Rating	57
2017	-0.46▲		Acc/Dis Rating	B
2018	5.18	7 4	Composite Rating	B
2019	-0.15	7 4	Timeliness Rating	91
2020	0.71▲	7 3	Sponsorship Rating	C
2021	0.91	9 5	EPS Growth Rate	N/A
2022	0.66 est	-27%▼	Earnings Stability	N/A
2023			P/E Ratio	12 (0.8 X SP)
			5-Year P/E Range	1-85
			Return on Equity	46%
			Cash Flow	\$0.89

Yield	NONE	Return on Equity		46%	
ExDiv	5/16/22	Cash Flow		\$0.89	
Book Value	x4.69	Debt	N/A	Ownership	
Inventory T/O	6.72X	R&D	7.4%	Mgmt	4%
U/D Vol Ratio	1.6	Alpha	0.40	Banks	0%
New CEO	10/2016	Beta	0.91	Funds	28%

Top RS in Grp	Symbol	RS	EPS Rtg	No. of Funds
BeliteBio	BLTE	99	59	Jun-21 223
Tricida	TCDA	99	37	Sep-21 229
RegencellBio	RGC	99	34	Dec-21 234
SierraOnco	SRRA	99	30	Mar-22 234
Pharvaris	PHVS	99	8	

Quarterly	EPS(\$)	%Chg	Sales(\$Mil)	% Chg
Jun-20	0.26	#+620%	40.4	+932%
Sep-20	0.31	#+999%	44.3	+446%
Dec-20	0.25	#+600%	37.7	+786%
Mar-21	-0.01	N/A	4.8	+84%
Jun-21	0.01	-96%	8.7	-79%
Sep-21	-0.04	N/A	4.9	-89%
Dec-21	0.96	+284%	115.4	+206%
Mar-22	-0.01	N/A	10.5	+119%



Year (Dec)	EPS (\$)	Price(\$) High Low	EPS Rating	Group RS Rating	SMR Rating
2015	0.47	5 2	76	85	A
2016	0.14▲	6 3			B+
2017	0.24▲	6 3			99
2018	0.22▲	6 2			B
2019	0.31	4 2			B
2020	-0.73▲	3 1			N/A
2021	0.95▲	12 1			N/A
2022	1.99	est 109%▼			15 (0.9 X SP)
2023	2.18	est 10%▼			3-217

Yield	NONE	Return on Equity	46%
ExDiv	12/21/17	Cash Flow	\$27.39
Book Value	x8.58	Debt	2%
Inventory T/O	N/A	R&D	N/A
U/D Vol Ratio	2.0	Alpha	0.89
New CEO	03/2014	Beta	1.36

Top RS in Grp	Symbol	RS	EPS Rtg	No. of Funds
Mantech	MANT	95	83	Jun-21 35
ePlus	PLUS	92	93	Sep-21 37
IBM	IBM	91	73	Dec-21 43
Amdocs	DOX	86	83	
Ibex	IBEX	86	51	Mar-22 45

Quarterly	EPS(\$)	%Chg	Sales(\$Mil)	% Chg
Jun-20	▲ -0.08	N/A	32.7	-36%
Sep-20	-0.02	N/A	31.6	-22%
Dec-20	▲ -0.15	N/A	41.2	-15%
Mar-21	0.08	#+118%	44.6	-1%
Jun-21	0.11	#+238%	48.9	+50%
Sep-21	▲ 0.24	#+999%	45.5	+44%
Dec-21	0.54	#+460%	64.9	+58%
Mar-22	0.62	+675%	82.0	+84%

Can RCMT continue its trend higher and resolve up out of this little consolidation?

